Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

229

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

September 30, 2005

Conditions
Alzheimer's DiseaseDementia
Interventions
DRUG

Donepezil hydrochloride

Trial Locations (42)

Unknown

Northport

Phoenix

Sun City

Tucson

San Francisco

Santa Monica

Torrance

Denver

Fort Lauderdale

Fort Myers

North Miami

St. Petersburg

Atlanta

Chicago

New Orleans

Springfield

Long Branch

Piscataway

New Hyde Park

Greenville

Raleigh

Centerville

Oklahoma City

Medford

Portland

Jenkintown

Austin

Houston

Randwick

Brisbane

Woodville South

Heidelberg West

Nedlands

Toronto

Hôpital Broca-La Rochefoucauld, Paris

Belfast

Saint Leonards-on-Sea

West End

Swindon

Bath

Blackpool

Bradford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT00096473 - Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter